576 related articles for article (PubMed ID: 28215400)
21. Association of MTOR Mutations With Developmental Brain Disorders, Including Megalencephaly, Focal Cortical Dysplasia, and Pigmentary Mosaicism.
Mirzaa GM; Campbell CD; Solovieff N; Goold C; Jansen LA; Menon S; Timms AE; Conti V; Biag JD; Adams C; Boyle EA; Collins S; Ishak G; Poliachik S; Girisha KM; Yeung KS; Chung BHY; Rahikkala E; Gunter SA; McDaniel SS; Macmurdo CF; Bernstein JA; Martin B; Leary R; Mahan S; Liu S; Weaver M; Doerschner M; Jhangiani S; Muzny DM; Boerwinkle E; Gibbs RA; Lupski JR; Shendure J; Saneto RP; Novotny EJ; Wilson CJ; Sellers WR; Morrissey M; Hevner RF; Ojemann JG; Guerrini R; Murphy LO; Winckler W; Dobyns WB
JAMA Neurol; 2016 Jul; 73(7):836-845. PubMed ID: 27159400
[TBL] [Abstract][Full Text] [Related]
22. Timing of mTOR activation affects tuberous sclerosis complex neuropathology in mouse models.
Magri L; Cominelli M; Cambiaghi M; Cursi M; Leocani L; Minicucci F; Poliani PL; Galli R
Dis Model Mech; 2013 Sep; 6(5):1185-97. PubMed ID: 23744272
[TBL] [Abstract][Full Text] [Related]
23. Insulin like growth factor-1-induced phosphorylation and altered distribution of tuberous sclerosis complex (TSC)1/TSC2 in C2C12 myotubes.
Miyazaki M; McCarthy JJ; Esser KA
FEBS J; 2010 May; 277(9):2180-91. PubMed ID: 20412061
[TBL] [Abstract][Full Text] [Related]
24. Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma.
Kwiatkowski DJ; Choueiri TK; Fay AP; Rini BI; Thorner AR; de Velasco G; Tyburczy ME; Hamieh L; Albiges L; Agarwal N; Ho TH; Song J; Pignon JC; Barrios PM; Michaelson MD; Van Allen E; Krajewski KM; Porta C; Pal S; Bellmunt J; McDermott DF; Heng DYC; Gray KP; Signoretti S
Clin Cancer Res; 2016 May; 22(10):2445-2452. PubMed ID: 26831717
[TBL] [Abstract][Full Text] [Related]
25. Dissecting the genetic basis of focal cortical dysplasia: a large cohort study.
Baldassari S; Ribierre T; Marsan E; Adle-Biassette H; Ferrand-Sorbets S; Bulteau C; Dorison N; Fohlen M; Polivka M; Weckhuysen S; Dorfmüller G; Chipaux M; Baulac S
Acta Neuropathol; 2019 Dec; 138(6):885-900. PubMed ID: 31444548
[TBL] [Abstract][Full Text] [Related]
26. Potential therapeutic targets for chordoma: PI3K/AKT/TSC1/TSC2/mTOR pathway.
Presneau N; Shalaby A; Idowu B; Gikas P; Cannon SR; Gout I; Diss T; Tirabosco R; Flanagan AM
Br J Cancer; 2009 May; 100(9):1406-14. PubMed ID: 19401700
[TBL] [Abstract][Full Text] [Related]
27. Somatic variants in diverse genes leads to a spectrum of focal cortical malformations.
Lai D; Gade M; Yang E; Koh HY; Lu J; Walley NM; Buckley AF; Sands TT; Akman CI; Mikati MA; McKhann GM; Goldman JE; Canoll P; Alexander AL; Park KL; Von Allmen GK; Rodziyevska O; Bhattacharjee MB; Lidov HGW; Vogel H; Grant GA; Porter BE; Poduri AH; Crino PB; Heinzen EL
Brain; 2022 Aug; 145(8):2704-2720. PubMed ID: 35441233
[TBL] [Abstract][Full Text] [Related]
28. Upregulation of the pathogenic transcription factor SPI1/PU.1 in tuberous sclerosis complex and focal cortical dysplasia by oxidative stress.
Zimmer TS; Korotkov A; Zwakenberg S; Jansen FE; Zwartkruis FJT; Rensing NR; Wong M; Mühlebner A; van Vliet EA; Aronica E; Mills JD
Brain Pathol; 2021 Sep; 31(5):e12949. PubMed ID: 33786950
[TBL] [Abstract][Full Text] [Related]
29. Distinct allelic variants of TSC1 and TSC2 in epilepsy-associated cortical malformations without balloon cells.
Majores M; Blümcke I; Urbach H; Meroni A; Hans V; Holthausen H; Elger CE; Schramm J; Galli C; Spreafico R; Wiestler OD; Becker AJ
J Neuropathol Exp Neurol; 2005 Jul; 64(7):629-37. PubMed ID: 16042315
[TBL] [Abstract][Full Text] [Related]
30. Somatic mutations rather than viral infection classify focal cortical dysplasia type II as mTORopathy.
Blümcke I; Sarnat HB
Curr Opin Neurol; 2016 Jun; 29(3):388-95. PubMed ID: 26840044
[TBL] [Abstract][Full Text] [Related]
31. PI3K/AKT pathway mutations cause a spectrum of brain malformations from megalencephaly to focal cortical dysplasia.
Jansen LA; Mirzaa GM; Ishak GE; O'Roak BJ; Hiatt JB; Roden WH; Gunter SA; Christian SL; Collins S; Adams C; Rivière JB; St-Onge J; Ojemann JG; Shendure J; Hevner RF; Dobyns WB
Brain; 2015 Jun; 138(Pt 6):1613-28. PubMed ID: 25722288
[TBL] [Abstract][Full Text] [Related]
32. Rhebbing up mTOR: new insights on TSC1 and TSC2, and the pathogenesis of tuberous sclerosis.
Kwiatkowski DJ
Cancer Biol Ther; 2003; 2(5):471-6. PubMed ID: 14614311
[TBL] [Abstract][Full Text] [Related]
33. mTOR signaling in epilepsy: insights from malformations of cortical development.
Crino PB
Cold Spring Harb Perspect Med; 2015 Apr; 5(4):. PubMed ID: 25833943
[TBL] [Abstract][Full Text] [Related]
34. FCD Type II and mTOR pathway: Evidence for different mechanisms involved in the pathogenesis of dysmorphic neurons.
Rossini L; Villani F; Granata T; Tassi L; Tringali G; Cardinale F; Aronica E; Spreafico R; Garbelli R
Epilepsy Res; 2017 Jan; 129():146-156. PubMed ID: 28056425
[TBL] [Abstract][Full Text] [Related]
35. Pathogenesis of tuberous sclerosis subependymal giant cell astrocytomas: biallelic inactivation of TSC1 or TSC2 leads to mTOR activation.
Chan JA; Zhang H; Roberts PS; Jozwiak S; Wieslawa G; Lewin-Kowalik J; Kotulska K; Kwiatkowski DJ
J Neuropathol Exp Neurol; 2004 Dec; 63(12):1236-42. PubMed ID: 15624760
[TBL] [Abstract][Full Text] [Related]
36. Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates increased severity of TSC2, compared with TSC1, disease in multiple organs.
Dabora SL; Jozwiak S; Franz DN; Roberts PS; Nieto A; Chung J; Choy YS; Reeve MP; Thiele E; Egelhoff JC; Kasprzyk-Obara J; Domanska-Pakiela D; Kwiatkowski DJ
Am J Hum Genet; 2001 Jan; 68(1):64-80. PubMed ID: 11112665
[TBL] [Abstract][Full Text] [Related]
37. Activation of extracellular regulated kinase and mechanistic target of rapamycin pathway in focal cortical dysplasia.
Patil VV; Guzman M; Carter AN; Rathore G; Yoshor D; Curry D; Wilfong A; Agadi S; Swann JW; Adesina AM; Bhattacharjee MB; Anderson AE
Neuropathology; 2016 Apr; 36(2):146-56. PubMed ID: 26381727
[TBL] [Abstract][Full Text] [Related]
38.
Ho DWH; Chan LK; Chiu YT; Xu IMJ; Poon RTP; Cheung TT; Tang CN; Tang VWL; Lo ILO; Lam PWY; Yau DTW; Li MX; Wong CM; Ng IOL
Gut; 2017 Aug; 66(8):1496-1506. PubMed ID: 27974549
[TBL] [Abstract][Full Text] [Related]
39. "Renal Cell Carcinoma With Leiomyomatous Stroma" Harbor Somatic Mutations of TSC1, TSC2, MTOR, and/or ELOC (TCEB1): Clinicopathologic and Molecular Characterization of 18 Sporadic Tumors Supports a Distinct Entity.
Shah RB; Stohr BA; Tu ZJ; Gao Y; Przybycin CG; Nguyen J; Cox RM; Rashid-Kolvear F; Weindel MD; Farkas DH; Trpkov K; McKenney JK
Am J Surg Pathol; 2020 May; 44(5):571-581. PubMed ID: 31850909
[TBL] [Abstract][Full Text] [Related]
40. mTOR Hyperactivity Levels Influence the Severity of Epilepsy and Associated Neuropathology in an Experimental Model of Tuberous Sclerosis Complex and Focal Cortical Dysplasia.
Nguyen LH; Mahadeo T; Bordey A
J Neurosci; 2019 Apr; 39(14):2762-2773. PubMed ID: 30700531
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]